Cord Blood Bank cGMP: 21 CFR 1271, BLA Pathway and FACT-NetCord Readiness
Cord blood banks in the United States operate under 21 CFR Part 1271 as HCT/P establishments, and — where they distribute unrelated allogeneic cord blood units for transplant — additionally under 21 CFR 600/610/630 with a Biologics License Application for each licensed cord blood product (HPC, Cord Blood).
In Short
- Public cord blood banks distribute unrelated allogeneic cord blood units — almost always under a BLA (HPC, Cord Blood is a licensed biologic) and almost always…
- Cord blood donor eligibility uniquely involves a maternal donor (medical history, infectious disease testing) and an infant assessment (delivery record, physical,…
- Cord blood processing — volume reduction, cryopreservation, vapour-phase liquid nitrogen storage — must be validated end-to-end with continuous storage temperature…
FACT-NetCord Standards (currently 7th edition) are the practical accreditation overlay for public banks and are required by NMDP for inventory inclusion. Private (family-directed) banks operate under 1271 only. This guide walks the integrated framework, the recurring findings, and a practical path to a defensible cord blood programme.
Public vs private and what regulatory floor applies
Public cord blood banks distribute unrelated allogeneic cord blood units — almost always under a BLA (HPC, Cord Blood is a licensed biologic) and almost always FACT-NetCord accredited as required by NMDP. Private (family-directed) banks store autologous or sibling-directed units and operate under 1271 alone (Section 361 HCT/P, intrafamily exception).
More on public vs private and what regulatory floor applies
A bank that operates both lines runs the higher floor on the entire facility — segregation of public and private inventory does not segregate the regulatory regime.
Maternal eligibility, infant assessment and the 1271/630 alignment
Cord blood donor eligibility uniquely involves a maternal donor (medical history, infectious disease testing) and an infant assessment (delivery record, physical, follow-up at month 6 and beyond for licensed units). The eligibility determination integrates the maternal file, the infant assessment and the testing results into one record per unit.
More on maternal eligibility, infant assessment and the 1271/630 alignment
Recurring finding: the maternal file is complete, the infant file is complete, but the integrated determination has no signature, no date, or no documented evaluation against eligibility criteria.
Processing, cryopreservation and the 10-year storage horizon
Cord blood processing — volume reduction, cryopreservation, vapour-phase liquid nitrogen storage — must be validated end-to-end with continuous storage temperature monitoring and a defined response to excursions. Storage typically extends 20+ years and the validation evidence must persist for the full storage horizon.
More on processing, cryopreservation and the 10-year storage horizon
Recurring finding: storage system validation is current but the trend data for the past 5+ years cannot be retrieved on the inspector's timeline.
Release for transplant: HLA, potency and the BLA-specific requirements
Release of a cord blood unit for transplant requires HLA typing (high-resolution by current standards), total nucleated cell and CD34+ cell content, viability, sterility, and — for licensed units — the BLA-specific release criteria. The release record must integrate all of these into one decision linked to the unit identifier and the transplant order.
More on release for transplant: HLA, potency and the BLA-specific requirements
The FACT-NetCord 7th edition tightened the release record requirements.
A 60-Day Readiness Path
- Days 1–10
scope check — public/private split and BLA applicability.
- Days 11–25
maternal-infant integrated determination audit.
- Days 26–40
cryopreservation validation and multi-year temperature trend retrieval.
- Days 41–50
release decision integrity audit.
- Days 51–60
integrated FACT-NetCord internal audit, management review and inspection readiness rehearsal.
Questions
Does a private cord blood bank need a BLA?
No — private (family-directed) cord blood banks operate as Section 361 HCT/P establishments under 21 CFR 1271 alone. The intrafamily exception removes the requirement for BLA. Distribution outside the family triggers the BLA pathway.
How long must cord blood records be retained?
§1271.270 sets 10 years post-administration as the floor; the practical retention horizon matches the storage horizon (often 20–25 years) plus 10 years post-release. Licensed BLA records carry their own retention requirements under 21 CFR 600 series.
Is FACT-NetCord required for public banks?
NMDP requires FACT-NetCord accreditation for inclusion of cord blood units in the NMDP inventory, which is the practical distribution channel for most US public banks. So while not legally mandatory, it is operationally required.
What is the 6-month follow-up requirement?
For licensed cord blood units (BLA), a follow-up assessment of the infant at approximately 6 months is required to confirm absence of conditions that would have disqualified the unit. This follow-up becomes part of the donor eligibility determination retrospectively.
Practical orientation, not legal advice. Rules differ by jurisdiction; your quality and compliance team decides what applies.
The Blood and Tissue Guide
Every unit identified. Every decision reviewed.
- Which rules reach your unit
- Receive, identify, quarantine
- Process, test, review
- Release, label, trace
Plus Evidence map and four worksheets.
Get the blood and tissue guideWe ask for your name and email so we can handle this request. The full guide then opens on this site, ready to translate, print or save. Privacy policy. Practical orientation, not legal advice; your quality unit decides which rules apply.
UltimateFree guide
The Blood and Tissue Guide
Every unit identified. Every decision reviewed.
Keep reading
21 CFR 1271 Readiness for Tissue and Cell Establishments- AABB Blood Bank Standards and 21 CFR 606 Readiness Guide
CAR T Cell Manufacturing Readiness: Chain of Identity and Release
Donor Eligibility, Lookback and Deviation Readiness
EU Tissues and Cells Directive 2004/23/EC and the SoHO Regulation
FACT-JACIE Accreditation Readiness for Cell Therapy